Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYMAKER-U06 Substudy 06E: Investigational Agents With Pembrolizumab ± Chemotherapy in First-line Esophageal Cancer
jRCT2041240166Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Jul 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label trial of pembrolizumab, ifinatamab deruxtecan and sacituzumab tirumotecan in Esophageal Squamous Cell Carcinoma (ESCC) (5 arms), sponsored by Merck & Co. Primary endpoints: Dose-limiting toxicities, Adverse events and 1 more. Started Jul 2025; status: recruiting.
02
Drugs
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on jRCT2041240166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041240166.